Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com
All News
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive.
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.
In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).
Highly purified synthetic trans-capsaicin (CNTX‐4975) injected directly into the joint reduced pain in chronic knee osteoarthritis (OA), data from the open-label phase III VICTORY-3 trial showed.
